TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8457308
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for cupulolithiasis
Study: 8457308
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for canalithiasis
Study: 17135854
Drug: Intervention cohort
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention cohort (n = 67) with lipid medication change during CR.
Study: 17135854
Drug: Control cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cohort (n = 178) with lipid medication change during CR.
Study: 12627040
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein with a medium dose of isoflavones (42 mg/day)
Study: 12627040
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein with a higher dose of isoflavones (58 mg/day)
Study: 15064585
Drug: r-hEPO administration
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hEPO administration
Study: 11394604
Drug: Intraarticular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine (5 mg)
Study: 7993153
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate (200 micrograms once daily)
Study: 8655886
Drug: Terfenadine tablets
Normalized name: terfenadine Oral Tablet
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine tablets (60 mg twice daily)
Study: 18688547
Drug: 25 mg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/week iron supplement
Study: 15246630
Drug: HPV16 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 L1 virus-like particle vaccine
Study: 11704601
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids alone or associated with oral steroids
Study: 11704601
Drug: Steroid-untreated asthmatics
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-untreated asthmatics
Study: 19317886
Drug: LEV XR
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV XR 1,000 mg/day
Study: 3898835
Drug: Antacid given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid given hourly
Study: 15972451
Drug: Aspirin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (150 mg/day) for hypercholesterolemics
Study: 12485551
Drug: Delayed antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotic prescriptions
Study: 25432415
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/extended-release (ER) niacin 2 g/day
Study: 25432415
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid 135 mg
Study: 30353590
Drug: 75 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g/kg S‐DDGS
Study: 30353590
Drug: 150 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g/kg S‐DDGS
Study: 30353590
Drug: 225 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 g/kg S‐DDGS
Study: 30353590
Drug: 300 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g/kg S‐DDGS
Study: 30353590
Drug: 0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/kg S‐DDGS (control)
Study: 22967500
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (7-hour duration)
Study: 15937294
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) administered via three infusions at Weeks 0, 2, and 6
Study: 20523253
Drug: diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 10 mg
Study: 30429050
Drug: Phased withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phased withdrawal of heart failure medications
Study: 30429050
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of heart failure medications
Study: 24223328
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (2 mg/kg)
Study: 24223328
Drug: Morphine spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine spray (0.05 mg/kg)
Study: 24223328
Drug: Ketamine spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine spray (0.5 mg/kg)
Study: 24223328
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline spray (8 puffs)
Study: 17961392
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride (2 times daily for 6 weeks, 1 capsule each time)
Study: 17961392
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (3 times daily for 6 weeks, 2 capsules each time)
Study: 15628826
Drug: rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline 1 mg
Study: 15628826
Drug: rasagiline 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline 5 mg
Study: 15628826
Drug: rasagiline 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline 10 mg
Study: 31613432
Drug: Usual oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oxygen therapy
Study: 31227278
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 8 weeks
Study: 31227278
Drug: Daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous 0.20-μg Teriparatide injection for 8 weeks (after 8 weeks of no treatment)
Study: 31227278
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 8 weeks (followed by Teriparatide treatment)
Study: 27665293
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (NFB, MPH, PA)
Study: 23520220
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) intervention for anger management, delivered over 12 weeks
Study: 23520220
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) intervention for anger management
Study: 21368386
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg/d
Study: 16260422
Drug: L-thyroxine substitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine substitution in hypothyroid patients
Study: 9799029
Drug: Potassium supplementation
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplementation (64 mmol/day of K as slow-release KCl tablets)
Study: 2793707
Drug: Almitrine (A)
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (A) 75 mg po
Study: 367713
Drug: Fenbufen 600
Normalized name: fenbufen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbufen 600 mg daily
Study: 7495975
Drug: High-purity factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-purity factor VIII preparations (ion-exchange S/D step)
Study: 7495975
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody factor VIII preparations
Study: 12085255
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use (three or more times per week for at least 6 months)
Study: 7900613
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin use
Study: 2132273
Drug: 1.5% oral
Normalized name: Baro-Cat, 1.5% oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% oral benzydamine spray applied six times per day (four sprays per application) for five days
Study: 24494277
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with auricular point sticking therapy (group A)
Study: 24494277
Drug: Clomiphene oral
Normalized name: clomiphene Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene oral administration (group B)
Study: 1854430
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy using the alpha-fraction of D. pteronyssinus
Study: 28802882
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.05 mg/kg)
Study: 28802882
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.05 mg/kg) in opioid-naive subjects
Study: 24114969
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg once daily
Study: 23846316
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/SAL) 250/50 μg bid
Study: 11684212
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (5 mL 7%)
Study: 11684212
Drug: Daily rhDNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhDNase vs Hypertonic saline
Study: 11684212
Drug: Daily rhDNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhDNase vs Alternate-day rhDNase
Study: 24053480
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 mg/day (dose escalation group)
Study: 21631570
Drug: Repaglinide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (1 mg, three times daily) for 8 weeks
Study: 16412157
Drug: Zolmitriptan 2.5
Normalized name: zolmitriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 2.5 mg
Study: 8645847
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B bladder irrigation (AmBBI) at 50 mg/L over 24 hours or 50 mg/L for 7 days
Study: 8645847
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole at 200 mg/d for 7 days
Study: 2140996
Drug: Nafarelin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin 400 micrograms daily
Study: 2140996
Drug: Danazol 600
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 600 mg daily
Study: 31600790
Drug: Control cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cohort (standard treatment)
Study: 30408001
Drug: Hexavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent vaccine (DTaP‐IPV‐HB‐PRP‐T) at 2 and 6 months, Pentavalent vaccine (DTaP‐IPV//PRP‐T) at 4 months
Study: 15271102
Drug: Continuous vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous vancomycin infusion (CVI)
Study: 15271102
Drug: Intermittent vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent vancomycin infusion (IVI)
Study: 19564877
Drug: diethylpropion 50
Normalized name: diethylpropion 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diethylpropion 50 mg BID
Study: 30192695
Drug: Ubiquinol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol (150 mg/day)
Study: 23426761
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg QD for 28 days
Study: 21420111
Drug: Tanezumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab (200 μg/kg, single intravenous dose)
Study: 27355532
Drug: Control (rabies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rabies vaccine)
Study: 8295879
Drug: pirazinamid administered
Normalized name: Pirazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pirazinamid administered at a single dose daily or each other day
Study: 3726454
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of neurotensin in relevant doses
Study: 2568849
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atracurium 0.125 mg kg‐1 + vecuronium 0.025 mg kg‐1
Study: 28868633
Drug: Low‐to‐medium‐potency topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐to‐medium‐potency topical corticosteroids (TCS)
Study: 27108464
Drug: Combined spinal-epidural
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal-epidural (CSE) with 0.5% heavy bupivacaine 2.5 mg
Study: 27108464
Drug: Low-dose epidural
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose epidural
Study: 23958597
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (30% protein [110 g/day], 40% carbohydrates [150 g/day], 30% fat [50 g/day])
Study: 23958597
Drug: Standard protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protein diet (15% protein [55 g/day], 55% carbohydrates [200 g/day], 30% fat [50 g/day])
Study: 19702089
Drug: Ginkgo leaf
Normalized name: Ginkgo leaf
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo leaf tablet (19.2 mg)
Study: 16849753
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) - orally, twice daily for 6 weeks
Study: 15262604
Drug: 8 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 microg/kg intrathecal morphine sulfate
Study: 8468114
Drug: Amikacin once
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin once daily (single injection)
Study: 8468114
Drug: Amikacin twice
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin twice daily (two injections at 12-hour interval)
Study: 23801529
Drug: lisdexamfetamine (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisdexamfetamine (30, 50 or 70 mg/day)
Study: 23801529
Drug: OROS-MPH (18,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-MPH (18, 36 or 54 mg/day)
Study: 15945502
Drug: Inhaled beta2-agonists,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta2-agonists, beclomethasone, disodiumcromoglycate, and immunotherapy (for 14 patients in group a and 28 patients in group b)
Study: 15945502
Drug: Inhaled beta2-agonists,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta2-agonists, beclomethasone, disodiumcromoglycate (without immunotherapy for 14 patients in group c)
Study: 2523664
Drug: Isradipine (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (0.5, 1.25, or 2.5 mg twice daily)
Study: 2897299
Drug: Propranolol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (240 mg)
Study: 951465
Drug: Oxprenolol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (320 mg)
Study: 3107495
Drug: Propranolol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (320 mg)
Study: 29799344
Drug: Ketamine (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.85 mg/kg/hr)
Study: 29799344
Drug: Ketamine (0.70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.70 mg/kg/hr)
Study: 15039245
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 300 mg bupropion (BUP)
Study: 11755834
Drug: Unoprostone 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unoprostone 0.15% twice daily
Study: 15036568
Drug: Betaxolol 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.5% twice daily
Study: 28387927
Drug: LDCT (Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDCT (Low Dose Computed Tomography)
Study: 25869689
Drug: Glucomannan (GNN)
DrugBank: Konjac mannan (DB14963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (GNN) at a dose of 3 g/day for 3 months
Study: 25869689
Drug: Placebo (maltodextrin)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin) at a dose of 3 g/day for 3 months
Study: 23713521
Drug: Tafluprost 0.0015%
Normalized name: TAFLUPROST 0.0015% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafluprost 0.0015% (Saflutan®) once daily
Study: 17160649
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) using morphine
Study: 1946567
Drug: Sensory cues
Normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sensory cues of cigarette smoking (with minimal nicotine, 0.5 mg)
Study: 1946567
Drug: Cigarette smoke
Normalized name: cigarette smoke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoke containing 0.5 mg of nicotine
Study: 6756019
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg morphine administered epidurally
Study: 6756019
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine administered epidurally
Study: 29281868
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (10 sessions of group therapy)
Study: 15974220
Drug: Battery-powered toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Battery-powered toothbrush (Oral-B Kids)
Study: 10492405
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg/ml (200 mg)
Study: 8922653
Drug: Ibandronate 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 5.0 mg
Study: 8922653
Drug: Ibandronate 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 0.25 mg
Study: 31353302
Drug: Single-injection ISB
Normalized name: ISB 1342
DrugBank: ISB 1342 (DB17251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection ISB
Study: 26758502
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (5 ml/d, 1.2 g/d n-3 long-chain PUFA)
Study: 20597040
Drug: Inhalation using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation using the Pari sinus device
Study: 12171453
Drug: Nutrient‐dense protein‐energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrient‐dense protein‐energy liquid supplement and encouragement to improve intake from other foods
Study: 2073488
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam (10 mg)
Study: 8138958
Drug: Morphine (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (20, 40 and 60 mg)
Study: 1376362
Drug: Naloxone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.1 and 0.2 mg)
Study: 31846499
Drug: rESWT on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: rESWT on agonist muscles (B)
Study: 20806703
Drug: Immediate preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate preparation with resin AH26 sealer
Study: 20806703
Drug: Delayed preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed preparation with resin AH26 sealer
Study: 20806703
Drug: Immediate preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate preparation with ZOE Dorifil sealer
Study: 20806703
Drug: Delayed preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed preparation with ZOE Dorifil sealer
Study: 15126715
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g x d of mixed CLA isomers for 8 wk
Study: 9512220
Drug: Gonadotrophin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin‐releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG)
Study: 21904641
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) supplementation at 1,200 mg daily for 7 days
Study: 2965374
Drug: Treatment B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: 6 mg/kg/day at 07.00 h and 6 mg/kg/day at 19.00 h
Study: 2965374
Drug: Treatment C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: 4 mg/kg/day at 07.00 h and 8 mg/kg/day at 19.00 h
Study: 24642580
Drug: Standard Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Triple Therapy (STT) - 10 days of treatment with esomeprazole, amoxicillin, and clarithromycin
Study: 24642580
Drug: Sequential Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Therapy (SQT) - 5 days of esomeprazole and amoxicillin, followed by 5 days of esomeprazole, clarithromycin, and tinidazole
Study: 24642580
Drug: Sequential Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Therapy (SQT) with isolated CLA-R
Study: 24642580
Drug: Sequential Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Therapy (SQT) with isolated MET-R
Study: 19527380
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron (III)-hydroxide polymaltose complex (Group III, n = 30)
Study: 16238560
Drug: Tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1 mg.kg(‐1) loading dose, 0.2 mg.kg(‐1) bolus doses)
Study: 16238560
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg.kg(‐1) loading dose, 0.02 mg.kg(‐1) bolus doses)
Study: 12668406
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy alone